Net Income (Loss) Per Share Attributable to Common Stockholders - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | 9 Months Ended | ||||
|---|---|---|---|---|---|---|
Sep. 30, 2026 |
Sep. 30, 2025 |
Sep. 30, 2026 |
Sep. 30, 2025 |
Jul. 19, 2026 |
Jul. 13, 2026 |
|
| Earnings Per Share [Abstract] | ||||||
| Dilutive effect of stock options, warrants and RSUs (in shares) | 1,713,545 | 0 | 0 | 0 | ||
| Dilutive effect of Roche convertible note (if-converted) (in shares) | 1,334,258 | 0 | 0 | 0 | ||
| Interest expense on convertible debt | $ 752 | $ 0 | ||||
| Warrants outstanding (in shares) | 14,003 | 14,003 | 428,560 | |||
| Warrant exercise price (in dollars per share) | $ 4.85 | $ 4.85 | $ 0.01 | $ 0.01 | ||
| Number of securities called by warrants (in shares) | 121,237 | 121,237 | ||||